サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536134

眼炎症治療の世界市場

Ocular Inflammation Treatment

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
眼炎症治療の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

眼炎症治療の世界市場は2030年までに11億米ドルに達する見込み

2023年に8億2,080万米ドルと推定される眼炎症治療の世界市場は、分析期間2023-2030年にCAGR 4.2％で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである副腎皮質ステロイドは、CAGR 5.0％を記録し、分析期間終了時には4億3,270万米ドルに達すると予測されます。免疫抑制剤セグメントの成長率は、分析期間中CAGR 4.2％と推定されます。

米国市場は2億2,360万米ドルと推定、中国はCAGR 8.0％で成長予測

米国の眼炎症治療市場は、2023年に2億2,360万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 8.0%で推移し、2030年には2億3,560万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と3.2%と予測されています。欧州では、ドイツがCAGR 2.3%で成長すると予測されています。

世界の眼炎症治療市場- 主要動向と促進要因のまとめ

ぶどう膜炎としても知られる眼炎症は、虹彩、毛様体、脈絡膜を含む眼球の中間層の炎症を特徴とする疾患です。この疾患は、感染症、自己免疫疾患、外傷など様々な原因によって引き起こされる可能性があり、速やかに治療を行わないと、視力低下を含む深刻な合併症を引き起こす可能性があります。眼炎症治療の主な目的は、炎症を抑え、痛みを和らげ、組織の損傷を防ぎ、正常な視力を回復させることです。一般的な治療法には副腎皮質ステロイドがあり、点眼、内服、注射などで投与します。また、自己免疫疾患によって炎症が引き起こされている場合には、免疫抑制剤が使用されます。どの治療を選択するかは、根本的な原因、炎症の重症度、患者固有の要因によって異なります。

最近の医療技術の進歩により、眼炎症に対する治療法は大幅に改善されました。免疫系の特定の成分を標的とする生物学的製剤は、特に従来の治療に抵抗性を示す重症のぶどう膜炎に対する効果的な治療法として登場しました。硝子体内注射や徐放性インプラントなどのドラッグデリバリーシステムの革新は、治療の有効性と利便性を高め、投与回数を減らし、患者のコンプライアンスを向上させています。さらに、光干渉断層計（OCT）や眼底フルオレセイン血管造影などの画像診断技術の進歩により、眼炎症のより早期かつ正確な発見が可能になり、タイムリーで的を絞った治療介入ができるようになりました。こうした技術的進歩は、ぶどう膜炎が視力の健康に及ぼす長期的な影響を軽減する上で極めて重要です。

眼炎症治療市場の成長は、ぶどう膜炎の有病率の上昇、目の健康に対する意識の高まり、人口の高齢化など、いくつかの要因によってもたらされます。診断や治療方法における技術の進歩は、より効果的で患者に優しい選択肢を提供することで市場拡大を後押ししています。生物学的製剤や先進ドラッグデリバリーシステムの導入により治療成績が大幅に向上し、ヘルスケアプロバイダーの間で採用が進んでいます。さらに、新興市場におけるヘルスケア支出の増加と眼科医療サービスへのアクセスの改善が、対応可能な市場を拡大しています。ぶどう膜炎の主な原因である自己免疫疾患の負担増も、眼炎症治療に対する需要の増加に寄与しています。患者教育の強化と慢性眼疾患の積極的な管理は、市場の成長をさらに後押ししています。このような動向が続く中、眼炎症治療市場は、ぶどう膜炎および関連疾患の管理改善と治療成績向上のための革新的なソリューションを提供し、持続的な成長を遂げる態勢を整えています。

調査対象企業の例（全86件）

  • AffaMed Therapeutics
  • Aldeyra Therapeutics
  • Alimera Sciences, Inc.
  • Bausch Health Companies Inc.
  • Cipla Ltd.
  • EyePoint Pharmaceuticals, Inc.
  • Formosa Pharmaceuticals, Inc.
  • Kiora Pharmaceutical
  • Kodiak Sciences
  • Laboratoires Thea
  • Ocular Therapeutix, Inc.
  • Oculis Labs
  • Rallybio
  • Tarsier Pharma
  • TearSolutions

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26859

Global Ocular Inflammation Treatment Market to Reach US$1.1 Billion by 2030

The global market for Ocular Inflammation Treatment estimated at US$820.8 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$432.7 Million by the end of the analysis period. Growth in the Immunosuppressants segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$223.6 Million While China is Forecast to Grow at 8.0% CAGR

The Ocular Inflammation Treatment market in the U.S. is estimated at US$223.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$235.6 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Ocular Inflammation Treatment Market - Key Trends and Drivers Summarized

Ocular inflammation, also known as uveitis, is a condition characterized by the inflammation of the middle layer of the eye, which includes the iris, ciliary body, and choroid. This condition can result from various causes such as infections, autoimmune disorders, or trauma, and can lead to serious complications including vision loss if not treated promptly. The primary goal of ocular inflammation treatment is to reduce inflammation, alleviate pain, prevent tissue damage, and restore normal vision. Common treatments include corticosteroids, which can be administered as eye drops, oral medications, or injections. Additionally, immunosuppressive agents are used in cases where inflammation is caused by autoimmune conditions. The choice of treatment depends on the underlying cause, severity of the inflammation, and patient-specific factors.

Recent advancements in medical technology have significantly improved the management of ocular inflammation. Biologic agents, which target specific components of the immune system, have emerged as effective treatments for severe cases of uveitis particularly those resistant to conventional therapies. Innovations in drug delivery systems, such as intravitreal injections and sustained-release implants, have enhanced the efficacy and convenience of treatments, reducing the frequency of administration and improving patient compliance. Furthermore, advancements in diagnostic techniques, including imaging technologies like optical coherence tomography (OCT) and fundus fluorescein angiography, have enabled earlier and more accurate detection of ocular inflammation, allowing for timely and targeted therapeutic interventions. These technological strides are pivotal in mitigating the long-term impact of uveitis on vision health.

The growth in the ocular inflammation treatment market is driven by several factors, including the rising prevalence of uveitis, increasing awareness about eye health, and the aging population. Technological advancements in diagnostics and treatment modalities are propelling market expansion by offering more effective and patient-friendly options. The introduction of biologic therapies and advanced drug delivery systems has significantly improved treatment outcomes, driving adoption among healthcare providers. Additionally, increased healthcare expenditure and improved access to eye care services in emerging markets are expanding the addressable market. The growing burden of autoimmune diseases, which are a major cause of uveitis, also contributes to the increased demand for ocular inflammation treatments. Enhanced patient education and proactive management of chronic eye conditions are further supporting market growth. As these trends continue, the ocular inflammation treatment market is poised for sustained growth, offering innovative solutions for better management and outcomes of uveitis and related conditions.

Select Competitors (Total 86 Featured) -

  • AffaMed Therapeutics
  • Aldeyra Therapeutics
  • Alimera Sciences, Inc.
  • Bausch Health Companies Inc.
  • Cipla Ltd.
  • EyePoint Pharmaceuticals, Inc.
  • Formosa Pharmaceuticals, Inc.
  • Kiora Pharmaceutical
  • Kodiak Sciences
  • Laboratoires Thea
  • Ocular Therapeutix, Inc.
  • Oculis Labs
  • Rallybio
  • Tarsier Pharma
  • TearSolutions

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Ocular Inflammation Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Innovations Propel Growth in Ocular Inflammation Treatment Market
    • Increasing Prevalence of Uveitis Drives Demand for Advanced Treatments
    • Rising Awareness About Eye Health Spurs Market Expansion
    • Aging Population Expands Addressable Market Opportunity
    • Advancements in Diagnostic Techniques Strengthen Business Case for Early Detection
    • Introduction of Biologic Therapies Generates Demand for Specialized Treatments
    • Advanced Drug Delivery Systems Propel Market Growth and Patient Compliance
    • Growing Burden of Autoimmune Diseases Drives Adoption of Ocular Inflammation Treatments
    • Improved Healthcare Expenditure in Emerging Markets Expands Market Reach
    • Integration of Imaging Technologies in Diagnosis Accelerates Market Penetration
    • Innovations in Treatment Modalities Propel Technological Advancements
    • Growing Consumer Preference for Minimally Invasive Procedures Spurs Adoption
    • Enhanced Clinical Outcomes Through Real-Time Monitoring Techniques
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ocular Inflammation Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ocular Inflammation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Injectables Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • JAPAN
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • CHINA
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • EUROPE
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Ocular Inflammation Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • FRANCE
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • GERMANY
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Ocular Inflammation Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • INDIA
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Ocular Inflammation Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Ocular Inflammation Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Ocular Inflammation Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • AFRICA
    • Ocular Inflammation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Ocular Inflammation Treatment by Drug Class - Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Ocular Inflammation Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants, Anti-Infectives and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Ocular Inflammation Treatment by Route Of Administration - Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Ocular Inflammation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Injectables Administration, Oral Administration and Other Routes of Administration for the Years 2014, 2024 & 2030

IV. COMPETITION